Author + information
- Takashi Hiromasa1,
- Shoichi Kuramitsu2,
- hiroyuki jinnouchi3,
- Takenori Domei4,
- Kyohei Yamaji5,
- Makoto Hyodo6,
- Yoshimitsu Soga7,
- Shinichi Shirai8 and
- Kenji Ando9
- 1Department of Cardiology Kokura Memorial Hospital, Kitakyushu, Japan
- 2kokura memorial hospital, Kitakyushu, Japan
- 3Kokura Memorial Hospital, Kitakyusyu, Japan
- 4Kokura memorial hospital, Kitakyusyu city, Japan
- 5Kitakyushu, Japan
- 6Kokura Memorial Hospital, Kitakyusyu, Japan
- 7Kokura Memorial Hospital
- 8Kokura Memorial Hospital, Kitakyushu, Japan
- 9Kokura Memorial Hosiptal
The aim of this study was to evaluate 3-year clinical outcome of patients treated with the Nobori biolimus-eluting stent (BES) compared to those with the Xience/Promus cobalt-chromium everolimus-eluting stent (EES) for unprotected left main disease (ULMD).
Between February 2010 and July 2012, a total of 153 patients undergoing percutaneous coronary intervention for ULMD (63 BES and 90 EES) were analyzed. We assessed the rates of major adverse cardiac events (MACE), defined as a composite of cardiac death, non-fatal myocardial infarction (MI), definite stent thrombosis (ST), and clinically driven target lesion revascularization (TLR) within 3-year.
Baseline patients and lesion characteristics were similar between BES and EES groups. No significant differences were observed with regard to lesion location (distal bifurcation lesion; 81.4% vs. 80.9%, p=0.93) and number of stent strategy (single stent strategy; 71.4% vs. 70.8%, p=0.93) between the 2 groups. The 3-year MACE rate was not significantly different between BES and EES groups (21.5% vs. 19.0%, p=0.83). The cumulative incidence of cardiac death, MI, ST, and clinically driven TLR rate were similar between the 2 groups (14.5% vs. 4.7%, p=0.07; 4.6% vs. 2.4%, p=0.45; 1.5% vs. 1.1%, p=0.86; 9.7% vs. 15.8%, p=0.30, respectively).
Three-year clinical outcome after BES implantation was not different from that after EES implantation for ULMD.
CORONARY: Complex and Higher Risk Procedures for Indicated Patients (CHIP)